

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Nintedanib for treating progressive fibrosing interstitial lung disease excluding idiopathic pulmonary fibrosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following comment was received at consultation that suggested that the appraisal might disadvantage patients with idiopathic pulmonary fibrosis:

“Assessing non-IPF patients only – disadvantages IPF patients who are declining and gave an FVC above 80%”

Other consultation comments indicated that there were no potential equality issues

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The comment quoted above was discussed at the scoping workshop and it was agreed that this issue does not relate to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Therefore, no changes were made to the scope as a result of this comment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No – see above

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Nicole Elliott

Date: 5/11/20